{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"\ud83e\ude7a Tutorial for the Ontology for the Simulation of Diseases (OSDi)","text":"<p>The Ontology for the Simulation of Diseases (OSDi) provides a structured and semantic framework for health technology assessment and simulation modeling. The ontology offers classes and properties to define all the key elements required to perform a cost-effectiveness analysis, i.e., diseases and their progression, populations, interventions, costs and utilities. In this tutorial, valid for version 1.0 of the ontology, we overview its main features and provide samples of use.</p> <p>OSDi serves as an interoperability framework for a number of use cases:  1. Extract information from a data source using an LLM 2. Automatically generate models (using JaDES-HTA) 3. Infer new knowledge from the available information</p> <p>The tutorial is intended for users familiar with ontologies and health economic models. If you are not familiar with ontologies, we frankly recommend starting with the Pizza tutorial. All the examples are expressed in Turtle format.</p> <p>After giving some details on the reference case, we will walk through:</p> <ol> <li>The disease and its progression</li> <li>The population</li> <li>Epidemiological parameters (incidence, screening characteristics)</li> <li>Progression parameters (probability of complications)</li> <li>Interventions and their effects (screening vs no screening)</li> <li>Utilities and calculated parameters</li> <li>The decision model that ties everything together</li> </ol>"},{"location":"before_start/","title":"Some tips before start","text":""},{"location":"before_start/#2-some-tips-before-start","title":"2. Some tips before start","text":"<p>In general, individuals of OSDi are expected to be defined in a separate file. All examples use Turtle (TTL) syntax and assume the following prefixes are declared:</p> <pre><code>@prefix osdi: https://w3id.org/ontologies-ULL/OSDi# .\n@prefix owl: http://www.w3.org/2002/07/owl# .\n@prefix rdfs: http://www.w3.org/2000/01/rdf-schema# .\n@prefix xsd: http://www.w3.org/2001/XMLSchema# .\n</code></pre> <p>The file with the individuals should import OSDi and the namespace should be something like <code>https://w3id.org/ontologies-ULL/OSDi/individuals/&lt;name&gt;</code>.</p> <pre><code>&lt;https://w3id.org/ontologies-ULL/OSDi/individuals/BD&gt; rdf:type owl:Ontology ;\n    rdfs:label \"OSDi BD individuals\"@en ;\n    rdfs:comment \"OSDi individuals for newborn screening of Biotinidase Deficiency, version 1.0. \"@en ;\n    owl:imports &lt;https://w3id.org/ontologies-ULL/OSDi/1.0&gt; .\n</code></pre> <p>Remember that all the components of OSDi  (classes, properties and common named individuals) are documented online.</p>"},{"location":"disease_representation/","title":"Disease and progression","text":""},{"location":"disease_representation/#3-disease-and-progression","title":"3. Disease and Progression","text":"<p>We will start by describing how to represent a disease and its progression using OSDi. We will just define the elements but not the parameters that characterize the progression and risks.</p>"},{"location":"disease_representation/#31-defining-the-disease","title":"3.1. Defining the Disease","text":"<p>The Disease (<code>osdi:Disease</code>) class is specialized using subtypes like <code>osdi:InheritedDisease</code> or <code>osdi:RareDisease</code>. The automated generation of models is expected to use this information in the future to infer the best model paradigm and structure based on this and other characteristics. </p> <p>BD is modeled as an inherited and rare disease using <code>osdi:InheritedDisease</code> and <code>osdi:RareDisease</code>. </p> <p>TTL Example:</p> <pre><code>osdi:BiotinidaseDeficiency\n    a osdi:InheritedDisease ,\n      osdi:RareDisease ;\n    rdfs:label \"Biotinidase deficiency\"@en ,\n               \"Deficiencia de biotinidasa\"@es ;\n    osdi:hasDescription \"\"\"\nInherited metabolic disorder caused by deficiency of the biotinidase enzyme.\nThe decision model distinguishes profound and partial biotinidase deficiency,\neach with its own untreated reference development.\n\"\"\"@en ;\n    osdi:hasSource \"10.1542/peds.2014-3399\"^^xsd:string .\n</code></pre>"},{"location":"disease_representation/#32-modeling-disease-progression","title":"3.2. Modeling Disease Progression","text":"<p>DiseaseProgression (<code>osdi:DiseaseProgression</code>) models how the disease develops. Its subclasses allow for different level of detail and characterize the different ways in which the disease signs and symptoms occur:</p> <ul> <li>Development (<code>osdi:Development</code>): A specific progression pathway, such as the natural history without screening. This is also useful when little detail is provided on the specific manifestations of a disease (e.g. you just need to model mild and severe developments)</li> <li>Manifestation (<code>osdi:Manifestation</code>): Specific symptoms categorized as Acute (<code>osdi:AcuteManifestation</code>) (e.g., seizures, hypotonia, skin problems) or Chronic (<code>osdi:ChronicManifestation</code>) (e.g., cognitive deficits, optic atrophy, hearing loss).</li> <li>Stage (<code>osdi:Stage</code>): Phases in the progression of a disease, such as those used to describe an oncological condition.</li> </ul> <p>All of these subclasses can be combined to create a detail view of the disease. Hence, you may define Stages or Manifestations specific to certain Development, and also Manifestations specific to certain Stage. For more complex structures, OSDi defines Disease Progression Sets (<code>osdi:DiseaseProgressionSet</code>). These sets include:    * CoexistentDiseaseProgressionSet (<code>osdi:CoexistentDiseaseProgressionSet</code>) describes a set of progressions (manifestations, stages...) that may occur simultaneously (e.g. retinopathy and nephropathy in diabetes).   * AlternativeDiseaseProgressionSet (<code>osdi:AlternativeDiseaseProgressionSet</code>) describes a set of progressions (manifestations, stages...) that are mutually exclusive, i.e., they can not occur simultaneously (e.g. mild and severe development of a disease).   * SequentialDiseaseProgressionSet (<code>osdi:SequentialDiseaseProgressionSet</code>) describes a set of progressions (manifestations, stages...) that appear sequentially. Unlike AlternativeDiseaseProgressionSet, where progressions may appear in any order, in this case each new progressions replaces the former.</p> <p>The two forms for BD (profound and partial) can be treated in many different ways in a model: we could define two different populations for each of the forms, and we could even consider them as different diseases. However, in this tutorial, we will consider them as Developments.</p> <p>TTL Example (Developments for forms of DB):</p> <pre><code>osdi:ProfoundBD_Development\n    a osdi:Development ;\n    rdfs:label \"Reference development of profound BD without screening\"@en ;\n    # Links to sets of acute and chronic manifestations, and death\n    osdi:hasDiseaseProgression osdi:BD_AcuteManifestationsSet ,\n                               osdi:BD_ChronicManifestationsSet ,\n                               osdi:BD_DiseaseRelatedDeath .\n\nosdi:BD_AcuteManifestationsSet\n    a osdi:CoexistentDiseaseProgressionSet ;\n    rdfs:label \"Acute manifestations of untreated profound BD\"@en ;\n    # Contains individual manifestations that may occur simultaneously\n    osdi:hasDiseaseProgression osdi:BD_Seizures ,\n                               osdi:BD_Hypotonia ,\n                               osdi:BD_SkinProblems .\n</code></pre>"},{"location":"model_structure/","title":"Model structure","text":""},{"location":"model_structure/#3-the-model-itself","title":"3. The Model Itself","text":"<p>The Model class (<code>osdi:Model</code>) is the central container for the entire HTA simulation. A user may create different models using the same individuals from the ontology. The most important property is </p> <p>The BD analysis is structured as a decision tree model.</p> OSDi Class Description BD Example (<code>osdi:BD_DecisionTreeModel</code>) <code>osdi:Model</code> The HTA simulation container <code>a osdi:DecisionTreeModel</code> <code>osdi:hasStrategy</code> Links to the interventions being compared <code>osdi:ScreeningStrategy_BD</code>, <code>osdi:NoScreeningStrategy_BD</code> <code>osdi:modelsDisease</code> Links to the primary disease under study <code>osdi:BiotinidaseDeficiency</code> <p>TTL Example:</p> <pre><code>osdi:BD_DecisionTreeModel\n    a osdi:DecisionTreeModel ;\n    rdfs:label \"Decision tree model for newborn screening of biotinidase deficiency\"@en ;\n    osdi:hasDescription \"\"\"\nA deterministic decision tree model comparing two strategies:\n(1) newborn screening for biotinidase deficiency with confirmatory testing and biotin treatment,\nand (2) no newborn screening (clinical detection only). \n\"\"\"@en ;\n    osdi:hasStrategy osdi:ScreeningStrategy_BD ,\n                     osdi:NoScreeningStrategy_BD ;\n    osdi:modelsDisease osdi:BiotinidaseDeficiency .\n</code></pre>"},{"location":"model_structure/#4-population-and-epidemiology","title":"4. Population and Epidemiology","text":""},{"location":"model_structure/#41-defining-population-subgroups","title":"4.1. Defining Population Subgroups","text":"<p>[cite_start]The Population (<code>osdi:Population</code>) class defines the target birth cohort for Spain [cite: 194] and its relevant subgroups (e.g., cases with profound BD) using the <code>osdi:isSubpopulationOf</code> property.</p> <p>TTL Example:</p> <pre><code>osdi:BD_BirthCohortPopulation\n    a osdi:Population ;\n    rdfs:label \"Birth cohort targeted by BD screening model\"@en .\n\nosdi:BD_ProfoundCasesPopulation\n    a osdi:Population ;\n    rdfs:label \"Newborns with profound biotinidase deficiency\"@en ;\n    osdi:isSubpopulationOf osdi:BD_BirthCohortPopulation .\n</code></pre>"},{"location":"model_structure/#42-epidemiological-parameters","title":"4.2. Epidemiological Parameters","text":"<p>[cite_start]EpidemiologicalParameter (<code>osdi:EpidemiologicalParameter</code>) captures population-level statistics like incidence, estimated from the Galicia NBS program [cite: 113-114]. The parameter is linked to the population it describes using <code>osdi:isParameterOf</code>.</p> <p>TTL Example (Incidence):</p> <pre><code>osdi:EPI_Incidence_ProfoundBD_Galicia\n    a owl:NamedIndividual , osdi:DeterministicParameter , osdi:EpidemiologicalParameter ;\n    rdfs:label \"Incidence of profound BD (Galicia NBS program)\"@en ;\n    osdi:hasDataItemType osdi:DI_Incidence ; # Epidemiological data item type\n    osdi:hasExpectedValue 0.0000147885 ;  # [cite_start]Value: 1 in 67 620 [cite: 128]\n    osdi:hasSource \"Galicia NBS program data; Vallejo-Torres et al. 2015...\"^^xsd:string ;\n    osdi:isParameterOf osdi:BD_BirthCohortPopulation .\n</code></pre>"},{"location":"model_structure/#5-parameters-costs-and-utilities","title":"5. Parameters, Costs, and Utilities","text":"<p>All quantifiable values are modeled as Parameter (<code>osdi:Parameter</code>) instances, differentiated by their Parameter Nature (e.g., <code>osdi:DeterministicParameter</code>) and Data Item Type (<code>osdi:DataItemType</code>).</p>"},{"location":"model_structure/#51-progression-probabilities","title":"5.1. Progression Probabilities","text":"<p>[cite_start]These are estimates of the probability of an outcome in untreated cases, based on meta-analysis of literature[cite: 132, 134].</p> <p>TTL Example (Probability of Seizures):</p> <pre><code>osdi:PROG_Seizures_ProfoundBD_ClinicallyDiagnosed\n    a owl:NamedIndividual , osdi:DeterministicParameter , osdi:Parameter ;\n    rdfs:label \"Probability of seizures in clinically diagnosed profound BD\"@en ;\n    osdi:hasDataItemType osdi:DI_Proportion ; # Data item type: Proportion/Probability\n    [cite_start]osdi:hasExpectedValue \"0.564\"^^xsd:double ; [cite: 128]\n    osdi:isParameterOf osdi:BD_Seizures .\n</code></pre>"},{"location":"model_structure/#52-costs","title":"5.2. Costs","text":"<p>[cite_start]Cost (<code>osdi:Cost</code>) parameters are expressed in 2013 US dollars [cite: 55] and linked to the resource (<code>osdi:HealthTechnology</code>) or adverse event (<code>osdi:DiseaseProgression</code>) they apply to.</p> <p>TTL Example (Unit Cost):</p> <pre><code>osdi:COST_ScreeningTest_BD_PerTest\n    a owl:NamedIndividual , osdi:DeterministicParameter , osdi:Parameter ;\n    rdfs:label \"Unit cost per BD screening test\"@en ;\n    osdi:hasDataItemType osdi:DI_UnitCost ;\n    osdi:hasExpectedValue \"1.23\"^^xsd:double ; # [cite_start]Cost in 2013 US dollars [cite: 143]\n    osdi:isParameterOf osdi:InitialScreeningTest_BD .\n</code></pre>"},{"location":"model_structure/#53-utilitiesdisutilities","title":"5.3. Utilities/Disutilities","text":"<p>[cite_start]Utility (<code>osdi:Utility</code>) models health-related quality of life (QoL) measures (QALYs)[cite: 52, 53]. [cite_start]If it represents a decrement in QoL, the <code>osdi:isDisutility</code> property is set to <code>true</code>[cite: 181].</p> <p>TTL Example (Disutility for Seizures):</p> <pre><code>osdi:UTIL_MildSeizureDisorder\n    a owl:NamedIndividual , osdi:Utility ;\n    rdfs:label \"Utility decrement for mild seizure disorder\"@en ;\n    osdi:hasDataItemType osdi:DI_Utility ;\n    [cite_start]osdi:hasExpectedValue \"0.040\"^^xsd:double ; [cite: 161]\n    osdi:isDisutility true ; # This is a QALY decrement (disutility)\n    osdi:isParameterOf osdi:BD_Seizures .\n</code></pre>"},{"location":"model_structure/#54-calculated-parameters","title":"5.4. Calculated Parameters","text":"<p>CalculatedParameter (<code>osdi:CalculatedParameter</code>) models values derived from an explicit formula involving other parameters. The example illustrates an annual cost calculation for follow-up.</p> <p>TTL Example (Annual Cost Calculation):</p> <pre><code>osdi:CALC_AnnualCost_TreatedBD_NoComplications\n    a owl:NamedIndividual , osdi:CalculatedParameter , osdi:Parameter ;\n    rdfs:label \"Annual cost of treated BD patient without complications\"@en ;\n    osdi:hasDataItemType osdi:DI_UnitCost ;\n    osdi:hasExpressionValue \"=COST_Biotin_Pack_5mg40Tablets*(365/30) + COST_SpecialistVisit*4 + COST_Audiometry + COST_VisualAcuityTest\"^^xsd:string ;\n    osdi:hasExpressionLanguage osdi:Exp_Excel .\n</code></pre>"},{"location":"model_structure/#6-interventions-and-strategy-implementation","title":"6. Interventions and Strategy Implementation","text":""},{"location":"model_structure/#61-defining-strategies-and-technologies","title":"6.1. Defining Strategies and Technologies","text":"<p>A Strategy (<code>osdi:Strategy</code>) defines a course of action. [cite_start]ScreeningStrategy (<code>osdi:ScreeningStrategy</code>) is the intervention being assessed [cite: 6][cite_start], compared to the No Screening Strategy (clinical detection)[cite: 61]. Strategies use HealthTechnology items (e.g., <code>osdi:Test</code> or <code>osdi:Drug</code>) via <code>osdi:usesHealthTechnology</code>.</p> <p>TTL Example (Screening Strategy):</p> <pre><code>osdi:ScreeningStrategy_BD\n    a osdi:ScreeningStrategy ;\n    rdfs:label \"Newborn screening for biotinidase deficiency\"@en ;\n    # Technologies used in the strategy: tests and treatment\n    osdi:usesTest osdi:InitialScreeningTest_BD ,\n                  osdi:ConfirmatoryTest_BD ;\n    osdi:usesTreatment osdi:BiotinTherapy .\n</code></pre>"},{"location":"model_structure/#62-modeling-intervention-effects-modifiers","title":"6.2. Modeling Intervention Effects (Modifiers)","text":"<p>The benefit of early detection and treatment is modeled using ModifierParameter (<code>osdi:ModifierParameter</code>). [cite_start]This parameter typically represents a Relative Risk and modifies the progression probabilities of the untreated disease under the intervention strategy [cite: 122-123]. For BD, the base case assumes a Relative Risk of 0 for all clinical symptoms if detected and treated early.</p> <p>TTL Example (Effect of Screening/Treatment):</p> <pre><code>osdi:MOD_CognitiveDeficit_ProfoundBD_ScreenedTreated\n    a owl:NamedIndividual , osdi:ModifierParameter , osdi:Parameter ;\n    rdfs:label \"Relative risk modifier for cognitive deficits in screened and treated profound BD\"@en ;\n    osdi:hasDataItemType osdi:DI_RelativeRisk ;\n    osdi:hasExpectedValue \"0.0\"^^xsd:double ; # Assumed Relative Risk (RR) of 0\n    # This modifier changes the baseline probability of cognitive deficits:\n    osdi:modifiesParameter osdi:PROG_CognitiveDeficit_ProfoundBD_ClinicallyDiagnosed .\n\nosdi:ScreeningStrategy_BD\n    # The strategy involves applying the modifier\n    osdi:involvesModification osdi:MOD_CognitiveDeficit_ProfoundBD_ScreenedTreated .\n</code></pre> <pre><code></code></pre>"},{"location":"reference_case/","title":"Explanation of the reference case","text":""},{"location":"reference_case/#1-reference-case-for-the-tutorial","title":"1. Reference case for the tutorial","text":"<p>The tutorial uses as a reference case, the model developed to assess the cost-effectiveness of adding Biotinidase Deficiency (BD) newborn screening (NBS) to the national NBS program in Spain, as described by Vallejo-Torres et al. (2015). The analysis takes the perspective of the Spanish National Health Service (NHS), using Quality-Adjusted Life Years (QALYs) as the measure of effectiveness. </p>"},{"location":"reference_case/#11-biotinidase-deficiency","title":"1.1. Biotinidase deficiency","text":"<ul> <li>Nature: BD is an autosomal recessive inherited disorder where the enzyme biotinidase is defective, preventing the recycling of the vitamin biotin.</li> <li>Forms: Categorized as profound BD (&lt;10% of normal activity) and partial BD (10%\u201330% of normal activity).</li> <li>Consequences (Untreated): Untreated profound BD can lead to severe neurologic and cutaneous symptoms including seizures, hypotonia, skin rash, alopecia, cognitive deficits, optic atrophy, and sensorineural hearing loss. Some consequences, like developmental delay, optic atrophy, and hearing loss, are generally irreversible once they occur.</li> <li>Incidence (Galicia, Spain): Combined BD incidence was estimated at 1 in 22,540 newborns, higher than the worldwide estimate.</li> </ul>"},{"location":"reference_case/#12-interventions-compared","title":"1.2. Interventions Compared","text":"<ol> <li>Screening Strategy (Intervention): Universal NBS for BD, including two initial screening tests, diagnostic confirmation, and lifelong oral biotin supplementation for confirmed cases. Cases detected early and treated are assumed to remain asymptomatic.</li> <li>No Screening Strategy (Comparator): Cases are detected only after the onset of clinical symptoms (clinical detection), leading to complications if not treated rapidly.</li> </ol>"}]}